Tempest Therapeutics (TPST) EBIT Growth (3y) (2015 - 2026)
Powered by 
Analysis
Tempest Therapeutics (TPST) EBIT Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 52.34% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 22.17% |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | -29.43% |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | - |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 28.05% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 27.50% |
| 10 | Tempest Therapeutics | 3.35 Mn | 2.55 Mn | - | 11.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.09% |
| Dec 31, 2025 | 23.01% |
| Sep 30, 2025 | 25.70% |
| Jun 30, 2025 | 3.17% |
| Mar 31, 2025 | -10.25% |
| Dec 31, 2024 | -23.78% |
| Sep 30, 2024 | -10.90% |
| Jun 30, 2024 | -12.19% |
| Mar 31, 2024 | -15.86% |
| Dec 31, 2023 | 39.70% |
| Sep 30, 2023 | -47.56% |
| Jun 30, 2023 | -12.56% |
| Mar 31, 2023 | 14.51% |
| Dec 31, 2022 | 11.37% |
| Sep 30, 2022 | 9.29% |
| Jun 30, 2022 | 4.77% |
| Mar 31, 2022 | 8.51% |
| Dec 31, 2021 | 8.86% |
| Sep 30, 2021 | 0.30% |
| Jun 30, 2021 | -10.82% |